Biotech Values

[dewophile]

"However, ribavirin’s low efficacy as a monotherapy does not imply that it has little incremental value in achieving RVR in combination with interferon; to the contrary, no less an authority than Josh Boger thinks that this is ribavirin’s main contribution in HCV therapy!"

did boger state this before or after PROVE 2 came out? because telaprevir and interferon without rib produces dramatic reductions in VL - way more than rib plus interferon - yet SVR in prove 2 for soc was better than telaprevir (minus rib). so it must follow that inhibition of relapse (and/or late rebound on treatment) is the primary moa by which rib acts to improve svr